1,8-Naphthyridine-3-carboxylicacid,1-cyclopropyl-6-fluoro-1,4-dihydro-7-[8-(methoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-4-oxo-;Zabofloxacin;1-cyclopropyl-6-fluoro-7-[(8E)-8-methoxyimino-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,8-naphthyridine-3-carboxylic acid;(E/Z)-zabofloxacin;LV66BA6V2G;Zabofloxacin [INN];Q27283202;1-Cyclopropyl-6-fluoro-7-(8-(methoxyimino)-2,6-diazaspiro(3.4)octan-6-yl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid;1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza-spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid;1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diazaspiro[3.4]octan-6-yl)-4-oxo-1,8-naphthyridine-3-carboxylic ac
Cas No.
219680-11-2
分子式
C19H20FN5O4
分子量
401.39
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
Zabofloxacin (DW-224a Free base) 是一种有效的、对细菌 II 型和 IV 型拓扑异构酶 (type II and IV topoisomerases) 有效的抑制剂。Zabofloxacin 对革兰氏阳性致病菌包括金黄色葡萄球菌、化脓性链球菌和肺炎链球菌有良好的抗菌活性。Zabofloxacin 是一种新型氟萘啶酮喹诺酮类抗生素,被认为是研究喹诺酮易感 (QSSP) 和喹诺酮耐药淋病 (QRSP) 的替代试剂。
生物活性
Zabofloxacin (DW-224a Free base) is a potent and seletive inhibitor of the bacterial type II and IV topoisomerases. Zabofloxacin has excellent activity against gram-positive pathogens including Steptococcus aureus, Streptococcus pyogenes and S.pneumonia. Zabofloxacin is a novel fluoronaphthyridone quinolone that is considered as an alternative antibiotic for treatment of quinolone-susceptible (QSSP) and quinolone-resistant gonorrhea (QRSP).
性状
Solid
IC50 & Target[1][2]
Topoisomerase I Topoisomerase II
体外研究(In Vitro)
Zabofloxacin shows a highly potent in vitro activity against clinical isolates of penicillin-sensitive S. pneumoniae (minimum inhibitory concentration, MIC90: 0.03 mg/L) and penicillin-resistant S. pneumoniae (MIC90: 0.03 mg/L). Against quinolone-resistant S. pneumoniae , zabofloxacin (MIC90: 1 mg/L) is more active than ciprofloxacin, sparfloxacin, and moxifloxacin. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Park HS, et al. Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae. Molecules. 2016 Nov 17;21(11). pii: E1562.